Related Experiment Video
Updated: Mar 29, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Use of ticagrelor in human pregnancy, the first experience
Marjan Verbruggen1, Dominique Mannaerts1, Joke Muys1
1Department of Obstetrics, UZA, Edegem, Belgium.
Abstract:
Ticagrelor was daily administered throughout pregnancy to a 37-year-old pregnant woman until 36 weeks of gestation. The patient, with Behçet disease, suffered from a non-ST elevation myocardial infarction 4 months before conception, possibly related to hypertension and tobacco abuse. Pregnancy and postpartum periods were uneventful. She delivered a healthy but small-for-gestational-age term neonate.
Related Concept Videos
Teratogenicity
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

